Bridging Known and Unknown Unknowns: From Natural Products and Their Mimics to Unmet Needs in Neuroscience
Scientific excursions into the unknown are often characterized by unanticipated twists and turns that may lead in directions that never could have been predicted. Decisions made during the course of these explorations determine what we discover. This Account chronicles one such journey that began wi...
Gespeichert in:
| Veröffentlicht in: | Accounts of chemical research Jg. 55; H. 17; S. 2397 |
|---|---|
| 1. Verfasser: | |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
06.09.2022
|
| Schlagworte: | |
| ISSN: | 1520-4898, 1520-4898 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Scientific excursions into the unknown are often characterized by unanticipated twists and turns that may lead in directions that never could have been predicted. Decisions made during the course of these explorations determine what we discover. This Account chronicles one such journey that began with a challenge encountered during the synthesis of a natural product and then unfolded over more than 30 years to focus on unmet needs in neuroscience. Specifically, while developing a concise approach to tetrahydroalstonine, a heteroyohimboid alkaloid having α-adrenergic activity, we faced the predicament of assembling a key intermediate. Solving this problem resulted in the serendipitous discovery of the vinylogous Mannich reaction and a productive program wherein we used this powerful construction as a key step in the syntheses of numerous alkaloids. However, we also realized that lessons learned from the synthesis of tetrahydroalstonine could be generalized to invent a new strategy for preparing diverse collections of substituted nitrogen heterocycles that could be screened against biological targets. The approach featured the combination of several reactants in a multicomponent assembly process to give a functionalized intermediate that could be elaborated by various ring-forming reactions to give heterocyclic scaffolds that could be further diversified. Screening these compound sets against a broad range of biological targets revealed some intriguing hits, but none of them led to a productive collaboration in translational research. Notwithstanding this setback, we screened curated members of our collections against proteins in the central nervous system and discovered some substituted B-norbenzomorphans that were selective for the enigmatic sigma-2 receptor (σ
R), an understudied protein that had been primarily associated with cancer. With scant knowledge of its role in neuroscience, we posited that small molecules that bind to σ
R might be neuroprotective, thus launching a new venture. In parallel investigations we prepared analogues of the initial hits, explored their effects in animal models of neurodegenerative and neurological conditions, and identified σ
R as transmembrane protein 97 (TMEM97). After first establishing the neuroprotective effects of several σ
R/TMEM97 ligands in a transgenic
model of neurodegeneration, we showed that one of these has procognitive effects and reduces levels of proinflammatory cytokines in a transgenic mouse model of Alzheimer's disease. We then identified a closely related σ
R/TMEM97 ligand that mitigates hippocampal-dependent memory deficits, prevents axon degeneration, and protects neurons and oligodendrocytes after traumatic brain injury. In a recent study, this compound was shown to protect retinal ganglion cells from retinal ischemia/reperfusion injury. In other collaborative investigations, we have shown that related, but structurally distinct, σ
R/TMEM97 ligands alleviate neuropathic pain, while a σ
R/TMEM97 ligand representing yet another chemotype reduces impairments associated with alcohol withdrawal. More recently, we have shown that σ
R/TMEM97 ligands enhance survival of cortical neurons in a neuronal model of Huntington's disease. Translational and mechanistic studies in these and other areas are in progress. Solving a problem we faced in natural product synthesis thus served as an unexpected gateway to discoveries that could lead to entirely new approaches to treat neurodegenerative and neurological conditions by targeting σ
R/TMEM97, a protein that has never been associated with these afflictions. |
|---|---|
| AbstractList | Scientific excursions into the unknown are often characterized by unanticipated twists and turns that may lead in directions that never could have been predicted. Decisions made during the course of these explorations determine what we discover. This Account chronicles one such journey that began with a challenge encountered during the synthesis of a natural product and then unfolded over more than 30 years to focus on unmet needs in neuroscience. Specifically, while developing a concise approach to tetrahydroalstonine, a heteroyohimboid alkaloid having α-adrenergic activity, we faced the predicament of assembling a key intermediate. Solving this problem resulted in the serendipitous discovery of the vinylogous Mannich reaction and a productive program wherein we used this powerful construction as a key step in the syntheses of numerous alkaloids. However, we also realized that lessons learned from the synthesis of tetrahydroalstonine could be generalized to invent a new strategy for preparing diverse collections of substituted nitrogen heterocycles that could be screened against biological targets. The approach featured the combination of several reactants in a multicomponent assembly process to give a functionalized intermediate that could be elaborated by various ring-forming reactions to give heterocyclic scaffolds that could be further diversified. Screening these compound sets against a broad range of biological targets revealed some intriguing hits, but none of them led to a productive collaboration in translational research. Notwithstanding this setback, we screened curated members of our collections against proteins in the central nervous system and discovered some substituted B-norbenzomorphans that were selective for the enigmatic sigma-2 receptor (σ
R), an understudied protein that had been primarily associated with cancer. With scant knowledge of its role in neuroscience, we posited that small molecules that bind to σ
R might be neuroprotective, thus launching a new venture. In parallel investigations we prepared analogues of the initial hits, explored their effects in animal models of neurodegenerative and neurological conditions, and identified σ
R as transmembrane protein 97 (TMEM97). After first establishing the neuroprotective effects of several σ
R/TMEM97 ligands in a transgenic
model of neurodegeneration, we showed that one of these has procognitive effects and reduces levels of proinflammatory cytokines in a transgenic mouse model of Alzheimer's disease. We then identified a closely related σ
R/TMEM97 ligand that mitigates hippocampal-dependent memory deficits, prevents axon degeneration, and protects neurons and oligodendrocytes after traumatic brain injury. In a recent study, this compound was shown to protect retinal ganglion cells from retinal ischemia/reperfusion injury. In other collaborative investigations, we have shown that related, but structurally distinct, σ
R/TMEM97 ligands alleviate neuropathic pain, while a σ
R/TMEM97 ligand representing yet another chemotype reduces impairments associated with alcohol withdrawal. More recently, we have shown that σ
R/TMEM97 ligands enhance survival of cortical neurons in a neuronal model of Huntington's disease. Translational and mechanistic studies in these and other areas are in progress. Solving a problem we faced in natural product synthesis thus served as an unexpected gateway to discoveries that could lead to entirely new approaches to treat neurodegenerative and neurological conditions by targeting σ
R/TMEM97, a protein that has never been associated with these afflictions. Scientific excursions into the unknown are often characterized by unanticipated twists and turns that may lead in directions that never could have been predicted. Decisions made during the course of these explorations determine what we discover. This Account chronicles one such journey that began with a challenge encountered during the synthesis of a natural product and then unfolded over more than 30 years to focus on unmet needs in neuroscience. Specifically, while developing a concise approach to tetrahydroalstonine, a heteroyohimboid alkaloid having α-adrenergic activity, we faced the predicament of assembling a key intermediate. Solving this problem resulted in the serendipitous discovery of the vinylogous Mannich reaction and a productive program wherein we used this powerful construction as a key step in the syntheses of numerous alkaloids. However, we also realized that lessons learned from the synthesis of tetrahydroalstonine could be generalized to invent a new strategy for preparing diverse collections of substituted nitrogen heterocycles that could be screened against biological targets. The approach featured the combination of several reactants in a multicomponent assembly process to give a functionalized intermediate that could be elaborated by various ring-forming reactions to give heterocyclic scaffolds that could be further diversified. Screening these compound sets against a broad range of biological targets revealed some intriguing hits, but none of them led to a productive collaboration in translational research. Notwithstanding this setback, we screened curated members of our collections against proteins in the central nervous system and discovered some substituted B-norbenzomorphans that were selective for the enigmatic sigma-2 receptor (σ2R), an understudied protein that had been primarily associated with cancer. With scant knowledge of its role in neuroscience, we posited that small molecules that bind to σ2R might be neuroprotective, thus launching a new venture. In parallel investigations we prepared analogues of the initial hits, explored their effects in animal models of neurodegenerative and neurological conditions, and identified σ2R as transmembrane protein 97 (TMEM97). After first establishing the neuroprotective effects of several σ2R/TMEM97 ligands in a transgenic Caenorhabditis elegans model of neurodegeneration, we showed that one of these has procognitive effects and reduces levels of proinflammatory cytokines in a transgenic mouse model of Alzheimer's disease. We then identified a closely related σ2R/TMEM97 ligand that mitigates hippocampal-dependent memory deficits, prevents axon degeneration, and protects neurons and oligodendrocytes after traumatic brain injury. In a recent study, this compound was shown to protect retinal ganglion cells from retinal ischemia/reperfusion injury. In other collaborative investigations, we have shown that related, but structurally distinct, σ2R/TMEM97 ligands alleviate neuropathic pain, while a σ2R/TMEM97 ligand representing yet another chemotype reduces impairments associated with alcohol withdrawal. More recently, we have shown that σ2R/TMEM97 ligands enhance survival of cortical neurons in a neuronal model of Huntington's disease. Translational and mechanistic studies in these and other areas are in progress. Solving a problem we faced in natural product synthesis thus served as an unexpected gateway to discoveries that could lead to entirely new approaches to treat neurodegenerative and neurological conditions by targeting σ2R/TMEM97, a protein that has never been associated with these afflictions.Scientific excursions into the unknown are often characterized by unanticipated twists and turns that may lead in directions that never could have been predicted. Decisions made during the course of these explorations determine what we discover. This Account chronicles one such journey that began with a challenge encountered during the synthesis of a natural product and then unfolded over more than 30 years to focus on unmet needs in neuroscience. Specifically, while developing a concise approach to tetrahydroalstonine, a heteroyohimboid alkaloid having α-adrenergic activity, we faced the predicament of assembling a key intermediate. Solving this problem resulted in the serendipitous discovery of the vinylogous Mannich reaction and a productive program wherein we used this powerful construction as a key step in the syntheses of numerous alkaloids. However, we also realized that lessons learned from the synthesis of tetrahydroalstonine could be generalized to invent a new strategy for preparing diverse collections of substituted nitrogen heterocycles that could be screened against biological targets. The approach featured the combination of several reactants in a multicomponent assembly process to give a functionalized intermediate that could be elaborated by various ring-forming reactions to give heterocyclic scaffolds that could be further diversified. Screening these compound sets against a broad range of biological targets revealed some intriguing hits, but none of them led to a productive collaboration in translational research. Notwithstanding this setback, we screened curated members of our collections against proteins in the central nervous system and discovered some substituted B-norbenzomorphans that were selective for the enigmatic sigma-2 receptor (σ2R), an understudied protein that had been primarily associated with cancer. With scant knowledge of its role in neuroscience, we posited that small molecules that bind to σ2R might be neuroprotective, thus launching a new venture. In parallel investigations we prepared analogues of the initial hits, explored their effects in animal models of neurodegenerative and neurological conditions, and identified σ2R as transmembrane protein 97 (TMEM97). After first establishing the neuroprotective effects of several σ2R/TMEM97 ligands in a transgenic Caenorhabditis elegans model of neurodegeneration, we showed that one of these has procognitive effects and reduces levels of proinflammatory cytokines in a transgenic mouse model of Alzheimer's disease. We then identified a closely related σ2R/TMEM97 ligand that mitigates hippocampal-dependent memory deficits, prevents axon degeneration, and protects neurons and oligodendrocytes after traumatic brain injury. In a recent study, this compound was shown to protect retinal ganglion cells from retinal ischemia/reperfusion injury. In other collaborative investigations, we have shown that related, but structurally distinct, σ2R/TMEM97 ligands alleviate neuropathic pain, while a σ2R/TMEM97 ligand representing yet another chemotype reduces impairments associated with alcohol withdrawal. More recently, we have shown that σ2R/TMEM97 ligands enhance survival of cortical neurons in a neuronal model of Huntington's disease. Translational and mechanistic studies in these and other areas are in progress. Solving a problem we faced in natural product synthesis thus served as an unexpected gateway to discoveries that could lead to entirely new approaches to treat neurodegenerative and neurological conditions by targeting σ2R/TMEM97, a protein that has never been associated with these afflictions. |
| Author | Martin, Stephen F |
| Author_xml | – sequence: 1 givenname: Stephen F orcidid: 0000-0002-4639-0695 surname: Martin fullname: Martin, Stephen F organization: Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35960884$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1OwzAYRS1URH_gDRDyyJJiO07isEHVAqIUhnaOvthOcUnsYidCvD1RKRLTPcO5d7hjNLDOaoQuKZlSwugNyDAFKV1n2zClkpAsi0_QiCaMRFzkYvCPh2gcwo4QwnianaFhnOQpEYKP0O7eG7U1doufrfuyGKzCG_tx4GOGW7zwrsEraDsPNX7zTnWyDQd3_a6Nxy-mMTLg1vWdRrd4pbUK2NgeOu-CNNpKfY5OK6iDvjjmBG0W8_XsMVq-PjzN7pYRxFy0EVQgiRJcqVxCmuQlTyGWjBCd5jkQSMoy56qkMospS6UkUJKKKhUrWsZpxdkEXf_u7r377HRoi8YEqesarHZdKFjW3yc4E6xXr45qVzZaFXtvGvDfxd8_7AdqSW2H |
| CitedBy_id | crossref_primary_10_3390_genes13122386 crossref_primary_10_1073_pnas_2306090120 crossref_primary_10_1039_D2SC02535C crossref_primary_10_1016_j_ejphar_2023_176251 crossref_primary_10_1021_acsptsci_5c00157 crossref_primary_10_59761_RCR5180 crossref_primary_10_1002_slct_202400901 crossref_primary_10_1016_j_prerep_2024_100023 crossref_primary_10_1016_j_cellsig_2024_111069 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1021/acs.accounts.1c00773 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Chemistry |
| EISSN | 1520-4898 |
| ExternalDocumentID | 35960884 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GroupedDBID | --- -DZ -~X 23M 4.4 53G 55A 5GY 5VS 5ZA 6J9 6P2 7~N 85S AABXI ABJNI ABMVS ABQRX ABUCX ACGFO ACGFS ACJ ACNCT ACS ADHLV AEESW AENEX AFEFF AFXLT AGXLV AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CGR CS3 CUPRZ CUY CVF D0L EBS ECM ED~ EIF F5P GGK GNL IH2 IH9 JG~ LG6 NPM P2P RNS ROL TWZ UI2 UPT VF5 VG9 W1F WH7 XSW YIN YZZ ZCA ~02 7X8 ABBLG ABLBI |
| ID | FETCH-LOGICAL-a348t-afac0d84dd9ca659b46a3c200e699a0a5bb94db1c73126cc0ab0f1dd3d1b36f42 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000841487700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1520-4898 |
| IngestDate | Fri Jul 11 08:03:36 EDT 2025 Wed Feb 19 02:26:04 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a348t-afac0d84dd9ca659b46a3c200e699a0a5bb94db1c73126cc0ab0f1dd3d1b36f42 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-4639-0695 |
| PMID | 35960884 |
| PQID | 2702184282 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2702184282 pubmed_primary_35960884 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-06 20220906 |
| PublicationDateYYYYMMDD | 2022-09-06 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Accounts of chemical research |
| PublicationTitleAlternate | Acc Chem Res |
| PublicationYear | 2022 |
| SSID | ssj0002467 |
| Score | 2.4561923 |
| Snippet | Scientific excursions into the unknown are often characterized by unanticipated twists and turns that may lead in directions that never could have been... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2397 |
| SubjectTerms | Alcoholism Alkaloids - pharmacology Animals Biological Products - pharmacology Ligands Mice Neuroprotective Agents Substance Withdrawal Syndrome |
| Title | Bridging Known and Unknown Unknowns: From Natural Products and Their Mimics to Unmet Needs in Neuroscience |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35960884 https://www.proquest.com/docview/2702184282 |
| Volume | 55 |
| WOSCitedRecordID | wos000841487700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qCnrx_VhfRPBatm3SNvEiurh4cMsedmVvZZqkUGXbdVv9_SZpy54EwUvbQwNhZpKZyWS-D6G7NFLac4NyIAPi0CzwHRCR7wghAp7qfCCwYDpvr1Ecs_mcT9oDt6q9VtntiXajlqUwZ-QD0zelsxGdITwsPx3DGmWqqy2FxibqER3KGKuO5mu0cJ9aBlntolyHMs661jnfG4Co9IQtH4O5fGRQbcjvQaZ1NqP9_07zAO21YSZ-bOziEG2o4gjtDDt2t2P0_mQ6tbTfwob4usBQSDwrPux3-67u8WhVLnAMFpsDTxpw2Mr-OzUFBjzOF7mocF3qMQtV41j7wgrnBY7XMJnqBM1Gz9Phi9PyLjhAKKuN2oQrGZWSCwiNykIgQi8nFXIOLgRpyqlMPRERzw-FcCF1M09KIr2UhBn1T9FWURbqHOFIBVrhXpjJkFM345ACZZ6XAZN-FES8j247MSZaAKZYAYUqv6pkLcg-Omt0kSwbAI6EBDrvYoxe_GH0Jdr1TceCqQGFV6iX6VWtrtG2-K7zanVjDUY_48n4Bwn-zWA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bridging+Known+and+Unknown+Unknowns%3A+From+Natural+Products+and+Their+Mimics+to+Unmet+Needs+in+Neuroscience&rft.jtitle=Accounts+of+chemical+research&rft.au=Martin%2C+Stephen+F&rft.date=2022-09-06&rft.eissn=1520-4898&rft.volume=55&rft.issue=17&rft.spage=2397&rft_id=info:doi/10.1021%2Facs.accounts.1c00773&rft_id=info%3Apmid%2F35960884&rft_id=info%3Apmid%2F35960884&rft.externalDocID=35960884 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1520-4898&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1520-4898&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1520-4898&client=summon |